Inhibition of TFF3 synergizes with c-MET inhibitors to decrease the CSC-like phenotype and metastatic burden in ER+HER2+ mammary carcinoma

Key Points

• Inhibition of tff3 significantly decreases the cancer stem cell-like phenotype in tumors, enhancing treatment efficacy.
• The study finds a reduction in metastatic burden, with specific metrics highlighting the effect of tff3 and c-met inhibitors combined.
• Analysis of mammary carcinoma models reveals potential benefits from targeting both tff3 and c-met together.
• This work highlights the need for further investigation into combination therapies to improve outcomes in ER+HER2+ breast cancer.